GlassScriptPhysician profile
Rochelle H Reech
NPI 1578945093
$4,740.89
in general payments reported to CMS, 2019-2025
29 companies · $543 in 2025
The $543 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $827 · 2022: $920 · 2023: $1,187 · 2024: $1,265 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,994.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,094.09 | 2021-2025 | General - Pain Management, Intracept |
| Collegium Pharmaceutical, INC. | $626.50 | 2021-2025 | Belbuca |
| Lundbeck LLC | $503.48 | 2022-2024 | Vyepti |
| Abbvie INC. | $363.43 | 2021-2025 | |
| Abbott Laboratories | $275.46 | 2021-2025 | Proclaim |
| Scilex Pharmaceuticals INC. | $234.36 | 2022-2025 | Ztlido |
| Relievant Medsystems, INC. | $226.90 | 2021-2023 | Intracept |
| Valinor Pharma, LLC | $223.17 | 2023-2025 | Movantik |
| Virtus Pharmaceuticals LLC | $145.39 | 2021-2025 | Levorphanol Tartrate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.74 | 2022-2025 | Relistor |
| Ibsa Pharma INC. | $126.43 | 2022-2025 | Tirosint, Tirosint, Licart |
| Nevro Corp. | $105.56 | 2021-2024 | Senza |
| Teva Pharmaceuticals USA, INC. | $86.77 | 2021-2023 | Ajovy |
| Arbor Pharmaceuticals, INC. | $81.07 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $76.98 | 2023-2024 | Horizant, Horizant |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $62.03 | 2022 | |
| Lilly USA, LLC | $59.50 | 2022-2023 | Reyvow, Emgality |
| Amgen INC. | $56.26 | 2022 | |
| Pfizer INC. | $49.36 | 2021-2023 | |
| Nalu Medical, INC. | $29.10 | 2024 | Nalu Neurostimulation System |
| Biodelivery Sciences International, INC. | $26.34 | 2021 | |
| Spinal Simplicity, LLC | $23.75 | 2023 | Ha Minuteman G3-R |
| Globus Medical, INC. | $20.98 | 2025 | Senza |
| Vertos Medical, INC. | $20.84 | 2024 | Mild Device Kit |
| Si-Bone, INC. | $18.79 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.03 | 2021 | |
| Bioventus LLC | $17.81 | 2023 | Durolane |
| Vertex Pharmaceuticals Incorporated | $17.08 | 2024 | |
| Novartis Pharmaceuticals Corporation | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rochelle Reech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.